Loading...

Wanbury

NSEI:WANBURY
Snowflake Description

Slightly overvalued with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
WANBURY
NSEI
₹380M
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The last earnings update was 308 days ago. More info.


Add to Portfolio Compare Print
  • Wanbury has significant price volatility in the past 3 months.
WANBURY Share Price and Events
7 Day Returns
21.3%
NSEI:WANBURY
0.6%
IN Pharmaceuticals
-0.5%
IN Market
1 Year Returns
-31.1%
NSEI:WANBURY
-9.7%
IN Pharmaceuticals
-2.4%
IN Market
WANBURY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Wanbury (WANBURY) 21.3% 0% -27% -31.1% -61.9% -38.1%
IN Pharmaceuticals 0.6% 2.2% -12.1% -9.7% -24.5% 5.2%
IN Market -0.5% -2% -4.8% -2.4% 21.3% 31.2%
1 Year Return vs Industry and Market
  • WANBURY underperformed the Pharmaceuticals industry which returned -9.7% over the past year.
  • WANBURY underperformed the Market in India which returned -2.4% over the past year.
Price Volatility
WANBURY
Industry
5yr Volatility vs Market

WANBURY Value

 Is Wanbury undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Wanbury to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Wanbury.

NSEI:WANBURY Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 24.8%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NSEI:WANBURY
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.732 (1 + (1- 35%) (664.46%))
2.938
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (2 * 8.6%)
24.75%

Discounted Cash Flow Calculation for NSEI:WANBURY using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Wanbury is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NSEI:WANBURY DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 24.75%)
2020 186.55 Est @ -9.63% 149.54
2021 178.20 Est @ -4.47% 114.51
2022 176.66 Est @ -0.87% 90.99
2023 179.58 Est @ 1.66% 74.15
2024 185.74 Est @ 3.43% 61.47
2025 194.40 Est @ 4.66% 51.58
2026 205.15 Est @ 5.53% 43.63
2027 217.73 Est @ 6.14% 37.12
2028 232.01 Est @ 6.56% 31.71
2029 247.92 Est @ 6.86% 27.16
Present value of next 10 years cash flows ₹681.85
NSEI:WANBURY DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= ₹247.92 × (1 + 7.55%) ÷ (24.75% – 7.55%)
₹1,550.24
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹1,550.24 ÷ (1 + 24.75%)10
₹169.82
NSEI:WANBURY Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹681.85 + ₹169.82
₹851.67
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹851.67 / 23.72
₹35.91
NSEI:WANBURY Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in NSEI:WANBURY represents 0.97297x of BSE:524212
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.97297x
Value per Share
(Listing Adjusted, INR)
= Value per Share (INR) x Listing Adjustment Factor
= ₹ 35.91 x 0.97297
₹34.93
Value per share (INR) From above. ₹34.93
Current discount Discount to share price of ₹16.20
= -1 x (₹16.20 - ₹34.93) / ₹34.93
53.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Wanbury is available for.
Intrinsic value
>50%
Share price is ₹16.2 vs Future cash flow value of ₹34.93
Current Discount Checks
For Wanbury to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Wanbury's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Wanbury's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Wanbury's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Wanbury's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:WANBURY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-03-31) in INR ₹-13.49
BSE:524212 Share Price ** BSE (2019-07-19) in INR ₹16.65
India Pharmaceuticals Industry PE Ratio Median Figure of 116 Publicly-Listed Pharmaceuticals Companies 16.68x
India Market PE Ratio Median Figure of 2,834 Publicly-Listed Companies 14.62x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Wanbury.

NSEI:WANBURY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:524212 Share Price ÷ EPS (both in INR)

= 16.65 ÷ -13.49

-1.23x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Wanbury is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
  • Wanbury is loss making, we can't compare the value of its earnings to the India market.
Price based on expected Growth
Does Wanbury's expected growth come at a high price?
Raw Data
NSEI:WANBURY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.23x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
India Pharmaceuticals Industry PEG Ratio Median Figure of 31 Publicly-Listed Pharmaceuticals Companies 1.48x
India Market PEG Ratio Median Figure of 535 Publicly-Listed Companies 1.29x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Wanbury, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Wanbury's assets?
Raw Data
NSEI:WANBURY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-03-31) in INR ₹-77.86
BSE:524212 Share Price * BSE (2019-07-19) in INR ₹16.65
India Pharmaceuticals Industry PB Ratio Median Figure of 135 Publicly-Listed Pharmaceuticals Companies 1.53x
India Market PB Ratio Median Figure of 3,669 Publicly-Listed Companies 0.94x
NSEI:WANBURY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:524212 Share Price ÷ Book Value per Share (both in INR)

= 16.65 ÷ -77.86

-0.21x

* Primary Listing of Wanbury.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Wanbury has negative assets, we can't compare the value of its assets to the IN Pharmaceuticals industry average.
X
Value checks
We assess Wanbury's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Wanbury has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

WANBURY Future Performance

 How is Wanbury expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wanbury has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.1%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Wanbury expected to grow at an attractive rate?
  • Unable to compare Wanbury's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Wanbury's earnings growth to the India market average as no estimate data is available.
  • Unable to compare Wanbury's revenue growth to the India market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NSEI:WANBURY Future Growth Rates Data Sources
Data Point Source Value (per year)
India Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.1%
India Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 11.1%
India Market Earnings Growth Rate Market Cap Weighted Average 17%
India Market Revenue Growth Rate Market Cap Weighted Average 9.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:WANBURY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:WANBURY Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2018-03-31 3,717 324 -320
2017-03-31 4,338 434 620
2016-03-31 4,233 431 -71

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Wanbury is high growth as no earnings estimate data is available.
  • Unable to determine if Wanbury is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:WANBURY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Wanbury Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:WANBURY Past Financials Data
Date (Data in INR Millions) EPS *
2018-03-31 -13.49
2017-03-31 29.80
2016-03-31 -3.58

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Wanbury will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Wanbury's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Wanbury's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Wanbury's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Wanbury has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

WANBURY Past Performance

  How has Wanbury performed over the past 5 years?

  • Wanbury's last earnings update was 308 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Wanbury's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Wanbury does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Wanbury's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Wanbury's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Wanbury's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Wanbury Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:WANBURY Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-03-31 3,716.67 -320.08 1,068.41
2017-03-31 4,338.09 620.15 1,114.28
2016-03-31 4,232.62 -71.46 1,086.93
2015-03-31 4,998.47 64.08 942.94
2014-09-30 4,412.38 -851.40 1,492.88
2013-03-31 4,591.06 -872.29 1,841.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Wanbury has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Wanbury has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Wanbury improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Wanbury's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Wanbury has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

WANBURY Health

 How is Wanbury's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Wanbury's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Wanbury's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Wanbury's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Wanbury's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Wanbury has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Wanbury Company Filings, last reported 1 year ago.

NSEI:WANBURY Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-03-31 -1,580.21 2,521.77 28.68
2017-03-31 -1,266.15 3,020.56 50.25
2016-03-31 -1,621.06 4,136.16 72.21
2015-03-31 -1,672.78 4,256.24 120.35
2014-09-30 -1,650.52 4,413.88 66.90
2013-03-31 -212.95 6,438.16 168.99
  • Wanbury has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Wanbury's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Wanbury has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Wanbury has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 30.5% per year.
X
Financial health checks
We assess Wanbury's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Wanbury has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

WANBURY Dividends

 What is Wanbury's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Wanbury dividends.
If you bought ₹2,000 of Wanbury shares you are expected to receive ₹0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Wanbury's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Wanbury's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:WANBURY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
India Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 74 Stocks 0.8%
India Market Average Dividend Yield Market Cap Weighted Average of 1446 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.6%
India Top 25% Dividend Yield 75th Percentile 2.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:WANBURY Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2011-05-30 0.000 0.000
2010-05-28 1.000 2.046
2009-03-31 0.000 0.000
2009-02-03 0.500 1.482

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Wanbury has not reported any payouts.
  • Unable to verify if Wanbury's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Wanbury's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Wanbury has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Wanbury's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Wanbury afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Wanbury has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

WANBURY Management

 What is the CEO of Wanbury's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Wanbury has no CEO, or we have no data on them.
Management Team Tenure

Average tenure of the Wanbury management team in years:

3.3
Average Tenure
  • The tenure for the Wanbury management team is about average.
Management Team

Vinod Verma

TITLE
Chief Financial Officer
COMPENSATION
₹12M
TENURE
3.3 yrs

Jitendra Gandhi

TITLE
Compliance Officer & Company Secretary
COMPENSATION
₹3M
TENURE
4.2 yrs

Shireesh Ambhaikar

TITLE
President of Operations - API Business
COMPENSATION
₹7M
TENURE
1.8 yrs

Prashant Menon

TITLE
Director of Sales and Marketing - Formulation Division
COMPENSATION
₹12M

K. Chandran

TITLE
Vice Chairman
AGE
61

Nanasaheb Gunjal

TITLE
Senior Vice President of QA
AGE
56
Board of Directors Tenure

Average tenure and age of the Wanbury board of directors in years:

6.2
Average Tenure
69
Average Age
  • The tenure for the Wanbury board of directors is about average.
Board of Directors

K. Chandran

TITLE
Vice Chairman
AGE
61

Narinder Puri

TITLE
Non-Executive Independent Director
COMPENSATION
₹470K
AGE
76
TENURE
14.3 yrs

S. Bhattacharya

TITLE
Non-Executive Independent Director
COMPENSATION
₹364K
AGE
69
TENURE
6.2 yrs

Pallavi Shedge

TITLE
Non-Executive Independent Woman Director
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
X
Management checks
We assess Wanbury's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Wanbury has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

WANBURY News

Simply Wall St News

If You Had Bought Wanbury (NSE:WANBURY) Stock Three Years Ago, You'd Be Sitting On A 58% Loss, Today

Because Wanbury is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … When a company doesn't make profits, we'd generally expect to see good revenue growth. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Simply Wall St -

Does The Wanbury Limited (NSE:WANBURY) Share Price Fall With The Market?

If you're interested in Wanbury Limited (NSE:WANBURY), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

What Kind Of Shareholders Own Wanbury Limited (NSE:WANBURY)?

The big shareholder groups in Wanbury Limited (NSE:WANBURY) have power over the company. … With a market capitalization of ₹457m, Wanbury is a small cap stock, so it might not be well known by many institutional investors. … We can zoom in on the different ownership groups, to learn more about WANBURY

Simply Wall St -

Wanbury Limited (NSE:WANBURY): What Does Its Beta Value Mean For Your Portfolio?

If you're interested in Wanbury Limited (NSE:WANBURY), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

How Does Wanbury Limited (NSE:WANBURY) Affect Your Portfolio Returns?

The first type is company-specific risk, which can be diversified away by investing in other companies to reduce exposure to one particular stock. … The other type of risk, which cannot be diversified away, is market risk. … Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few.

Simply Wall St -

Breaking Down Wanbury Limited's (NSE:WANBURY) Ownership Structure

Check out our latest analysis for Wanbury NSEI:WANBURY Ownership_summary May 16th 18 Institutional Ownership WANBURY's 15.59% institutional ownership seems enough to cause large share price movements in the case of significant share sell-off or acquisitions by institutions, particularly when there is a low level of public shares available on the market to trade. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: WANBURY's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

Can Wanbury Limited (NSE:WANBURY) Improve Your Portfolio Returns?

If you are looking to invest in Wanbury Limited’s (NSEI:WANBURY), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … Wanbury has a beta of 1.24, which means that the percentage change in its stock value will be higher than the entire market in times of booms and busts.

Simply Wall St -

Interested In Wanbury Limited (NSE:WANBURY)? Here's How It Performed Recently

I like to use the ‘latest twelve-month’ data, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … Each year, for the past half a decade Wanbury's revenue growth has been relatively subdued, with an annual growth rate of 1.34%, on average. … The intrinsic value infographic in our free research report helps visualize whether WANBURY is currently mispriced by the market?

Simply Wall St -

What You Must Know About Wanbury Limited's (NSE:WANBURY) Major Investors

Today, I will be analyzing Wanbury Limited’s (NSEI:WANBURY) recent ownership structure, an important but not-so-popular subject among individual investors. … View our latest analysis for Wanbury NSEI:WANBURY Ownership_summary Feb 1st 18 Institutional Ownership With an institutional ownership of 16.56%, WANBURY can face volatile stock price movements if institutions execute block trades on the open market, more so, when there are relatively small amounts of shares available on the market to trade Although WANBURY has a high institutional ownership, such stock moves, in the short-term, are more commonly linked to a particular type of active institutional investors – hedge funds. … With 6.40% ownership, WANBURY insiders is an important ownership type.

Simply Wall St -

Is Wanbury Limited (NSE:WANBURY) Still A Cheap Healthcare Stock?

Wanbury Limited (NSEI:WANBURY), a ₹1.05B small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population, impacting the sector globally. … This rate is larger than the growth rate of the Indian stock market as a whole. … NSEI:WANBURY PE PEG Gauge Jan 24th 18 The pharmaceutical sector's PE is currently hovering around 29.5x, relatively similar to the rest of the Indian stock market PE of 28.4x.

Simply Wall St -

WANBURY Company Info

Description

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, neutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes under approximately 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Details
Name: Wanbury Limited
WANBURY
Exchange: NSEI
Founded: 1988
₹379,521,872
23,720,117
Website: http://www.wanbury.com
Address: Wanbury Limited
BSEL Tech Park, B-Wing,
10th Floor,
Navi Mumbai,
Maharashtra, 400703,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 524212 Equity Shares Mumbai Stock Exchange IN INR 07. Feb 2005
NSEI WANBURY Equity Shares National Stock Exchange of India IN INR 07. Feb 2005
Number of employees
Current staff
Staff numbers
2,137
Wanbury employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/19 12:50
End of day share price update: 2019/07/19 00:00
Last earnings filing: 2018/09/14
Last earnings reported: 2018/03/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.